Masahiro Ieko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Masahiro Ieko has a total of 194 co-authors. Here are the top co-authors by number of shared publications:
Sumiyoshi Naito
Department of Clinical Laboratory, Health Sciences University of Hokkaido Hospital, Ishikari-Tobetsu, Japan
26 shared publicationsMika Yoshida
Department of Clinical Laboratory, Health Sciences University of Hokkaido Hospital, Sapporo, Hokkaido, Japan
21 shared publications- Nobuhiko Takahashi
Department of Internal Medicine, School of Dentistry, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Hokkaido, Japan
11 shared publications Kazumasa Ohmura
Institute of Preventive Medical Science, Health Sciences University of Hokkaido Hospital, Sapporo, Hokkaido, Japan
10 shared publications- Osamu Kumano
Health and Medical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST) Takamatsu Japan
10 shared publications Nobuhiko Takahashi
Department of Internal Medicine, School of Dentistry, Health Sciences University of Hokkaido, Ishikari 061-0293, Japan
7 shared publications
Latest Publications
- 17 June 2026
- Published by Elsevier in Thrombosis Research
- Vol. 264, 109754
Cytochalasins modulate donor responsiveness in functional assays for heparin-induced thrombocytopenia
- 17 June 2026
- Published by Elsevier in Thrombosis Research
- Vol. 264, 109754
Cytochalasins modulate donor responsiveness in functional assays for heparin-induced thrombocytopenia
- 5 June 2026
- Published by Springer Nature in International Journal of Hematology
- Vol. 124 (4) , 547-558
Influence of time, temperature, and mechanical agitation on whole-blood and plasma sample stability in coagulation tests
Preanalytical variables strongly influence coagulation test results; however, their combined effects remain insufficiently evaluated. This study examined whole-blood and plasma stability under conditions mimicking current sample storage and transport practices, focusing on three variables: time, temperature, and mechanical agitation. Coagulation tests were performed using four manufacturers' systems, and sample stability was assessed using percentage changes with a 10% criterion and statistical analysis. Among all conditions tested, frozen plasma was consistently the most stable across assays. Whole blood stored at room temperature showed relatively smaller changes, whereas refrigerated whole blood exhibited the largest variation, with factor VIII activity and von Willebrand factor antigen levels decreasing to ≤ 30% even in samples obtained from healthy participants. In some refrigerated samples, clotting times shortened, leading to false-negative lupus anticoagulant results. Mechanical agitation had only marginal effects compared with time and temperature. Sample stability differed substantially between whole blood and plasma and across test types, and the alteration of sample quality accelerated depending on time and temperature conditions, leading to variable testing results. This study underscores the importance of immediate frozen plasma preparation after blood collection to prevent misinterpretation in clinical practice, particularly when prolonged storage is unavoidable, as in outsourced testing.
- 5 June 2026
- Published by Springer Nature in International Journal of Hematology
- Vol. 124 (4) , 547-558
Influence of time, temperature, and mechanical agitation on whole-blood and plasma sample stability in coagulation tests
Preanalytical variables strongly influence coagulation test results; however, their combined effects remain insufficiently evaluated. This study examined whole-blood and plasma stability under conditions mimicking current sample storage and transport practices, focusing on three variables: time, temperature, and mechanical agitation. Coagulation tests were performed using four manufacturers' systems, and sample stability was assessed using percentage changes with a 10% criterion and statistical analysis. Among all conditions tested, frozen plasma was consistently the most stable across assays. Whole blood stored at room temperature showed relatively smaller changes, whereas refrigerated whole blood exhibited the largest variation, with factor VIII activity and von Willebrand factor antigen levels decreasing to ≤ 30% even in samples obtained from healthy participants. In some refrigerated samples, clotting times shortened, leading to false-negative lupus anticoagulant results. Mechanical agitation had only marginal effects compared with time and temperature. Sample stability differed substantially between whole blood and plasma and across test types, and the alteration of sample quality accelerated depending on time and temperature conditions, leading to variable testing results. This study underscores the importance of immediate frozen plasma preparation after blood collection to prevent misinterpretation in clinical practice, particularly when prolonged storage is unavoidable, as in outsourced testing.
- Open Access
- 23 April 2025
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 47 (5) , 923-930
Variability of Argatroban Effects on the Multiple APTT Reagents in High and Low Coagulation Activity Samples
Introduction: Argatroban is routinely monitored using activated partial thromboplastin time (APTT), with a recommended target range of 1.5–3.0 times. Although this range was established based on clinical trial data, including several APTT reagents, the differences in reactivity among APTT reagents remain unclear. This study compared the reactivity of six commercial APTT reagents to argatroban in normal and abnormal plasma samples.Materials and Methods: Normal samples were spiked with argatroban and five abnormal samples: low coagulation factor activity, high factor VIII, high factor VIIa, low fibrinogen, and high fibrinogen. Drug concentrations were adjusted to 0, 0.5, 1.0, 1.5, and 2.0 μg/mL in each plasma. Six APTT reagents, including silica or ellagic acid activator and phospholipids derived from synthetic or natural sources, were tested.Results: The APTT ratio range among the six reagents was 2.4–3.2 in normal plasma at a concentration of 2.0 μg/mL. The sample showing the most expanded range was low coagulation activity (3.3–5.2), and the range in the sample with high factor VIII activity decreased (1.5–2.2).Conclusions: A reactivity difference was observed in argatroban‐spiked samples, which increased in abnormal plasma samples. APTT may not reflect the anticoagulant activity of argatroban in patients with abnormal coagulation activity. The reactivity of APTT should be confirmed in each laboratory, and patient background coagulation status should be assessed before monitoring is conducted using the APTT ratio.
- 23 April 2025
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 47 (5) , 923-930
Open AccessVariability of Argatroban Effects on the Multiple APTT Reagents in High and Low Coagulation Activity Samples
Introduction: Argatroban is routinely monitored using activated partial thromboplastin time (APTT), with a recommended target range of 1.5–3.0 times. Although this range was established based on clinical trial data, including several APTT reagents, the differences in reactivity among APTT reagents remain unclear. This study compared the reactivity of six commercial APTT reagents to argatroban in normal and abnormal plasma samples.Materials and Methods: Normal samples were spiked with argatroban and five abnormal samples: low coagulation factor activity, high factor VIII, high factor VIIa, low fibrinogen, and high fibrinogen. Drug concentrations were adjusted to 0, 0.5, 1.0, 1.5, and 2.0 μg/mL in each plasma. Six APTT reagents, including silica or ellagic acid activator and phospholipids derived from synthetic or natural sources, were tested.Results: The APTT ratio range among the six reagents was 2.4–3.2 in normal plasma at a concentration of 2.0 μg/mL. The sample showing the most expanded range was low coagulation activity (3.3–5.2), and the range in the sample with high factor VIII activity decreased (1.5–2.2).Conclusions: A reactivity difference was observed in argatroban‐spiked samples, which increased in abnormal plasma samples. APTT may not reflect the anticoagulant activity of argatroban in patients with abnormal coagulation activity. The reactivity of APTT should be confirmed in each laboratory, and patient background coagulation status should be assessed before monitoring is conducted using the APTT ratio.
- 14 February 2025
- Published by Elsevier in Journal of Cardiology
- Vol. 85 (6) , 473-479
Development of new anticoagulants targeting coagulation factor XI and prospects for clinical use
- 14 February 2025
- Published by Elsevier in Journal of Cardiology
- Vol. 85 (6) , 473-479
Development of new anticoagulants targeting coagulation factor XI and prospects for clinical use
- 9 February 2024
- Published by Springer Nature in International Journal of Hematology
- Vol. 119 (4) , 407-415
Age-related variation in coagulation factors in non-valvular atrial fibrillation patients receiving direct oral anticoagulants
Age is a significant risk factor for ischemic stroke. However, the influence of aging on coagulation parameters in non-valvular atrial fibrillation (NVAF) patients treated with direct oral anticoagulants (DOACs) remains unclear. A total of 775 samples were collected from 224 NVAF patients receiving apixaban, edoxaban or rivaroxaban. The samples were categorized into three age groups: (i) ≤ 64 years, (ii) 65–74 years, and (iii) ≥ 75 years (apixaban: N = 48, 108, 119; edoxaban: N = 63, 68, 126; rivaroxaban: N = 115, 90, 38, respectively). Coagulation parameters including fibrinogen (Fbg), factor II, factor V, factor VII, factor X, and D-dimer, were compared between the three age groups for each drug. The slopes in the correlation between drug concentrations and modified diluted prothrombin time (mdPT) were also assessed. Fbg and factor V increased with age, while factor II and factor X decreased. Factor VII and D-dimer showed no significant differences across age categories. The slope in response to drug concentrations was similar between the age groups. In NVAF patients treated with apixaban, edoxaban and rivaroxaban, some coagulation parameters exhibited age-related variation. However, the response of mdPT to drug concentration was consistent across age categories.
- 9 February 2024
- Published by Springer Nature in International Journal of Hematology
- Vol. 119 (4) , 407-415
Age-related variation in coagulation factors in non-valvular atrial fibrillation patients receiving direct oral anticoagulants
Age is a significant risk factor for ischemic stroke. However, the influence of aging on coagulation parameters in non-valvular atrial fibrillation (NVAF) patients treated with direct oral anticoagulants (DOACs) remains unclear. A total of 775 samples were collected from 224 NVAF patients receiving apixaban, edoxaban or rivaroxaban. The samples were categorized into three age groups: (i) ≤ 64 years, (ii) 65–74 years, and (iii) ≥ 75 years (apixaban: N = 48, 108, 119; edoxaban: N = 63, 68, 126; rivaroxaban: N = 115, 90, 38, respectively). Coagulation parameters including fibrinogen (Fbg), factor II, factor V, factor VII, factor X, and D-dimer, were compared between the three age groups for each drug. The slopes in the correlation between drug concentrations and modified diluted prothrombin time (mdPT) were also assessed. Fbg and factor V increased with age, while factor II and factor X decreased. Factor VII and D-dimer showed no significant differences across age categories. The slope in response to drug concentrations was similar between the age groups. In NVAF patients treated with apixaban, edoxaban and rivaroxaban, some coagulation parameters exhibited age-related variation. However, the response of mdPT to drug concentration was consistent across age categories.
- Open Access
- 30 August 2023
- Published by Open Exploration Publishing in Exploration of Immunology
- Vol. 3 (4) , 286-299
Considerations for simultaneous detection of autoantibodies to coagulation factor and lupus anticoagulant
In patients with autoimmune coagulation factor deficiency (AiCFD), the production of autoantibodies that inhibit coagulation factors in the blood reduces the activity of those relevant coagulation factors, resulting in severe bleeding symptoms. Recently, reports of patients with AiCFD have noted the concomitant detection of lupus anticoagulant (LA), a risk factor for thrombosis. LA-positive patients may show bleeding symptoms due to decreased activity of coagulation factor II (FII) caused by autoantibodies against FII, in addition to thrombotic symptoms, a condition termed LA-hypoprothrombinemia syndrome (LAHPS). Anti-FII antibodies in LAHPS cases are frequently cleared antibodies that can be detected using immunological techniques, such as enzyme-linked immunosorbent assay (ELISA). Recently, several cases of coagulation FV inhibitors, known as autoimmune FV deficiency, have been reported. Some of these cases may be complicated by LA, which can cause thrombosis. False-positive results for anticoagulant inhibitors are known to occur in LA cases; therefore, immunological confirmation of antibodies against coagulation factors is recommended. Additionally, acquired hemophilia A (AHA), caused by autoantibodies against FVIII, is a typical acquired hemorrhagic diathesis, although affected patients may present with thrombosis associated with LA. Thus, it is important to remember that hemorrhagic diathesis due to autoantibodies against clotting factors can also result in thrombosis, as demonstrated by the co-detection of LA. When clotting factor inhibitors are detected in LA-positive individuals, it is important to confirm the presence of autoantibodies against coagulation factors using immunological methods, such as ELISA, to avoid false-positive results.
- 30 August 2023
- Published by Open Exploration Publishing in Exploration of Immunology
- Vol. 3 (4) , 286-299
Open AccessConsiderations for simultaneous detection of autoantibodies to coagulation factor and lupus anticoagulant
In patients with autoimmune coagulation factor deficiency (AiCFD), the production of autoantibodies that inhibit coagulation factors in the blood reduces the activity of those relevant coagulation factors, resulting in severe bleeding symptoms. Recently, reports of patients with AiCFD have noted the concomitant detection of lupus anticoagulant (LA), a risk factor for thrombosis. LA-positive patients may show bleeding symptoms due to decreased activity of coagulation factor II (FII) caused by autoantibodies against FII, in addition to thrombotic symptoms, a condition termed LA-hypoprothrombinemia syndrome (LAHPS). Anti-FII antibodies in LAHPS cases are frequently cleared antibodies that can be detected using immunological techniques, such as enzyme-linked immunosorbent assay (ELISA). Recently, several cases of coagulation FV inhibitors, known as autoimmune FV deficiency, have been reported. Some of these cases may be complicated by LA, which can cause thrombosis. False-positive results for anticoagulant inhibitors are known to occur in LA cases; therefore, immunological confirmation of antibodies against coagulation factors is recommended. Additionally, acquired hemophilia A (AHA), caused by autoantibodies against FVIII, is a typical acquired hemorrhagic diathesis, although affected patients may present with thrombosis associated with LA. Thus, it is important to remember that hemorrhagic diathesis due to autoantibodies against clotting factors can also result in thrombosis, as demonstrated by the co-detection of LA. When clotting factor inhibitors are detected in LA-positive individuals, it is important to confirm the presence of autoantibodies against coagulation factors using immunological methods, such as ELISA, to avoid false-positive results.
- 16 September 2022
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 45 (1) , 119-125
Evaluation of newly‐developed modified diluted prothrombin time reagent in non‐valvular atrial fibrillation patients with direct oral anticoagulants: A comparative study with conventional reagents
Introduction: A single assay to assess the effect of the direct FXa inhibitor is needed clinically because prothrombin (PT) assay is not yet sensitive enough for accurate evaluation. We developed modified diluted prothrombin time (mdPT) assay showing a high reactivity to direct FXa inhibitors based on prothrombin time (PT) reagent. The purpose of this study was to evaluate the reactivity of mdPT to direct FXa inhibitors comparing to that of commercial PT reagents and diluted prothrombin time (dPT).Methods: The correlation and slopes of mdPT against the drug concentrations by anti‐Xa assay were compared to those of the four commercial reagents of PT or dPT in 275, 257, and 243 clinical samples collected from non‐valvular atrial fibrillation (NVAF) patients who are prescribed apixaban, edoxaban or rivaroxaban for stroke prevention, respectively.Results: The correlation coefficient (95% confidence interval) of mdPT against apixaban, edoxaban, and rivaroxaban was 0.818 (0.775–0.854), 0.914 (0.892–0.932), and 0.814 (0.766–0.852), respectively. The slope (95% confidence interval) of mdPT for apixaban, edoxaban, and rivaroxaban was 0.0068 (0.0063–0.0075), 0.0076 (0.0072–0.0080), and 0.0072 (0.0065–0.0078), respectively, which were higher than that of four commercial PT and dPT reagents, ranging within 0.0006–0.0023, 0.0017–0.0038, and 0.0016–0.0057 (all, p < 0.001), respectively.Conclusion: Compared with other PT and dPT reagents, mdPT reagent showed sharper slope to all direct FXa inhibitors, and higher correlation to apixaban and comparable correlation to edoxaban and rivaroxaban. This new reagent is expected to be a coagulation screening assay having a consistently high response to any types of direct FXa inhibitors.
- 16 September 2022
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 45 (1) , 119-125
Evaluation of newly‐developed modified diluted prothrombin time reagent in non‐valvular atrial fibrillation patients with direct oral anticoagulants: A comparative study with conventional reagents
Introduction: A single assay to assess the effect of the direct FXa inhibitor is needed clinically because prothrombin (PT) assay is not yet sensitive enough for accurate evaluation. We developed modified diluted prothrombin time (mdPT) assay showing a high reactivity to direct FXa inhibitors based on prothrombin time (PT) reagent. The purpose of this study was to evaluate the reactivity of mdPT to direct FXa inhibitors comparing to that of commercial PT reagents and diluted prothrombin time (dPT).Methods: The correlation and slopes of mdPT against the drug concentrations by anti‐Xa assay were compared to those of the four commercial reagents of PT or dPT in 275, 257, and 243 clinical samples collected from non‐valvular atrial fibrillation (NVAF) patients who are prescribed apixaban, edoxaban or rivaroxaban for stroke prevention, respectively.Results: The correlation coefficient (95% confidence interval) of mdPT against apixaban, edoxaban, and rivaroxaban was 0.818 (0.775–0.854), 0.914 (0.892–0.932), and 0.814 (0.766–0.852), respectively. The slope (95% confidence interval) of mdPT for apixaban, edoxaban, and rivaroxaban was 0.0068 (0.0063–0.0075), 0.0076 (0.0072–0.0080), and 0.0072 (0.0065–0.0078), respectively, which were higher than that of four commercial PT and dPT reagents, ranging within 0.0006–0.0023, 0.0017–0.0038, and 0.0016–0.0057 (all, p < 0.001), respectively.Conclusion: Compared with other PT and dPT reagents, mdPT reagent showed sharper slope to all direct FXa inhibitors, and higher correlation to apixaban and comparable correlation to edoxaban and rivaroxaban. This new reagent is expected to be a coagulation screening assay having a consistently high response to any types of direct FXa inhibitors.
- 24 May 2022
- Published by Springer Nature in International Journal of Hematology
- Vol. 116 (1) , 152-154
Lupus anticoagulant-hypoproaccelerin (factor V) syndrome (LAHPS-V): a new hemorrhagic condition associated with lupus anticoagulant
- 24 May 2022
- Published by Springer Nature in International Journal of Hematology
- Vol. 116 (1) , 152-154
Lupus anticoagulant-hypoproaccelerin (factor V) syndrome (LAHPS-V): a new hemorrhagic condition associated with lupus anticoagulant
- Open Access
- 1 January 2022
- Published by XMLink in Journal of Gastric Cancer
- Vol. 22 (1) , 47-55
Bleeding After Gastric Endoscopic Submucosal Dissection Focused on Management of Xa Inhibitors
Ono S, et al. J Gastric Cancer. 2022 Feb;22:e2. https://doi.org/10.5230/jgc.2022.22.e2
- 1 January 2022
- Published by XMLink in Journal of Gastric Cancer
- Vol. 22 (1) , 47-55
Open AccessBleeding After Gastric Endoscopic Submucosal Dissection Focused on Management of Xa Inhibitors
Ono S, et al. J Gastric Cancer. 2022 Feb;22:e2. https://doi.org/10.5230/jgc.2022.22.e2